Merck & Co., Inc. MRK
148.78
0.80
0.54%
as of 25 Sep
- Market cap
- $365.4B
- P/E
- 119×
Follow MRK
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Merck & Co., Inc. (MRK) Book value per share
Merck & Co., Inc.'s book value per share at the end of fiscal 2025 was 21.0×, up 14.9% from 18.3× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 17.0×. Over the past ten years it has ranged from 10.0× (fiscal 2020) to 21.0× (fiscal 2025) — the current reading is the highest in ten years. Merck & Co., Inc. ranks 9th of 21 Drug Manufacturers General companies by book value per share.
Book value per share, annual
Annual
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 21.0× | 14.93% |
| FY2024 | 18.3× | 23.46% |
| FY2023 | 14.8× | (18.45%) |
| FY2022 | 18.2× | 20.30% |
| FY2021 | 15.1× | 50.59% |
| FY2020 | 10.0× | (0.94%) |
| FY2019 | 10.1× | 0.46% |
| FY2018 | 10.1× | (20.31%) |
| FY2017 | 12.7× | (13.11%) |
| FY2016 | 14.6× | (8.33%) |
Quarterly
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 17.0× | (8.52%) |
| Mar 2026 | 18.6× | (11.72%) |
| Dec 2025 | 21.0× | 1.17% |
| Sep 2025 | 20.8× | 6.44% |
| 42 more quarters | Free account |
Against its own ten years
Low 10.0×
High 21.0×
Ten-year median
14.8×
Current reading's percentile
100
Book value per share against peers
| Company | Book value per share |
|---|---|
| JNJ Johnson & Johnson compare | 35.3× |
| AZN AstraZeneca PLC compare | 32.5× |
| NVS Novartis AG compare | 22.0× |
| AMGN Amgen Inc. compare | 21.6× |
| MRK Merck & Co., Inc. | 17.0× |
| PFE Pfizer Inc. compare | 15.0× |
| GILD Gilead Sciences, Inc. compare | 9.4× |
| NVO Novo Nordisk A/S compare | 7.8× |
| ABBV AbbVie Inc. compare | −3.3× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on MRK
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- The full statement